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NICE has made an important change to Clinical Guideline 64 (CG64)(1) adding the word 
µURXWLQHO\¶WRRecommendation 1.1.3: ³$QWLELRWLFSURSK\OD[LVDJDLQVWLQIHFWLYHHQGRFDUGLWLVLV
not recommended routinely for people undergoing dental procedures´  In a letter about the 
change to the MP Chris Philp (2), Sir Andrew Dillon, CEO of NICE, confirmed that  ³« in 
LQGLYLGXDOFDVHVDQWLELRWLFSURSK\OD[LVPD\EHDSSURSULDWH´   
 
Why has this changed occurred? 
This change followed approaches to Sir Andrew Dillon by Chris Philp and the widow of a 
patient with a replacement aortic valve who died from infective endocarditis (IE) developing 
after unprotected dental scaling.  Their case included:  
 
1) Evidence that antibiotic prophylaxis is effective in people at high risk of IE having 
high risk dental procedures (see box)(3).  There are no randomized controlled trials.  
However a French community study (4) showed a 14 times higher incidence of IE in people 
with prosthetic valves having unprotected dental procedures (1/10,700) compared with 
protected procedures (1/149,000).  Horstkotte (5) found no cases of IE in 229 people with 
prosthetic valves having protected dental procedures compared with 2 of 117 (1.7%) having 
unprotected procedures.  A recent retrospective analysis of hospital-acquired data in the UK 
(6) suggested that 277 patients at all levels of risk needed to have antibiotic prophylaxis to 
prevent one episode of IE.    
2) The observed increase in the incidence of IE in the UK since the original 2008 NICE  
guidance was introduced.  The risk of IE has been increasing constantly in the USA and 
Europe.  However an interrupted time sequence study (6) showed that this rate accelerated in 
the UK after 2008 with an estimated 35 extra cases of IE every month over the next 5 years 
after the change  above the expected number based on the pre-2008 incidence.  This was 
associated with an 88% fall in prescriptions of antibiotics.       
3) Limitations of the NICE process (3).  The NICE process is well-designed for its original 
purpose of making decisions about the cost-effectiveness of drug therapies or procedures for 
which randomized controlled trial data are available.  However it is not appropriate for 
questions of clinical judgement for which other types of evidence exist.  NICE assessed only 
a small proportion of the available evidence and made a number of errors of interpretation 
including underestimating the risk of patients with prosthetic valve developing IE and 
underestimating the bacteraemia arising as a result of invasive dental procedures (3).  NICE 
grossly overestimated the risks of antibiotic prophylaxis and this contributed to a decision that 
antibiotic prophylaxis was not cost-effective.  In fact adverse-effects from oral amoxicillin 
prophylaxis are uncommon with no deaths reported in Europe since records began (7) 
although clindamicin has a slightly higher level of risk (8).  Both are cost-effective in high-risk 
patients having high-risk dental procedures (8).    
4) A change in the law of consent (9-11).    It is now necessary for dentists to appraise their 
patient of the differences between NICE and other guidelines if it is likely that they would have 
a special interest, for example if they have a replacement heart valve or prior IE (12).  The 
patient should then be allowed to make up their own mind whether or not to have antibiotic 
prophylaxis.   GMC/GDC standards and the advice of the medical/dental defence 
RUJDQLVDWLRQVKLJKOLJKWWKHQHHGIRUWKLVGLVFXVVLRQDQGWKHSDWLHQW¶VGHFLVLRQWREH recorded 
in the clinical records. 
 
Is IE caused by poor oral hygiene or dental extractions? 
Oral organisms account for approximately 40% of cases of IE.  There is a tendency to regard 
the mechanism by which these cause IE as either poor dental hygiene or dental procedures 
as if these are mutually exclusive.  This misunderstanding probably underlies some of the 
opposition to targeted antibiotic prophylaxis shown by NICE and other commentators.  In fact 
both mechanisms are likely to contribute.  In a recent study (13), 68 patients had IE thought to 
be of oral origin, 60 attributed to poor oral health and 8 to dental procedures.  The larger 
proportion of these cases might be prevented by improving dental care, but the smaller 
proportion would still require antibiotic prophylaxis before the procedure.  The person whose 
death from IE led to the recent approach to NICE had good oral hygiene.  
 
How does this affect clinical practice? 
Although the dentist is responsible for consent, the patient will have to be made aware if they 
are at high-risk of IE and this is the prime responsibility of a cardiologist specialising in valve 
disease.   Patients under continuing cardiology surveillance should expect to receive 
education (14) and a summary of advice about antibiotic prophylaxis in a letter which can be 
shown to their dentist.  However many patients with prior endocarditis or replacement valves 
are cared for solely in the community (15) and for these the dentist should consider seeking 
advice from a cardiologist .  Sometimes the dentist refuses DSDWLHQW¶VUHTXHVWto have 
antibiotic prophylaxis although this may become less frequent with the latest modification of 
NICE guidance.   General practitioners may then be asked to intercede and are often willing 
to issue a prescription, but otherwise should seek advice from a cardiologist.  Their general 
practitioner or cardiologist could consider advising the patient and their dentist on the level of 
risk in a letter.  Prophylaxis for adults should be with amoxicillin 3 g by mouth one hour before 
the procedure or, for patients with penicillin hypersensitivity, clindamicin 600 mg orally.   
 
Staff in general practices should emphasise that good oral hygiene and regular dental review 
are as important as antibiotic prophylaxis, if not more so, in reducing the risk of IE (7).  The 
ESC recommend (12) strict dental and cutaneous hygiene with regular dental surveillance 
(see box).   It is also important to educate patients at moderate and high risk in recognizing 
the possibility of IE.  Typically there may be persistent night-sweats, general malaise and 
weight-loss.  At least two sets of blood cultures should be taken before starting antibiotics.  
The British Heart Foundation produce warning cards that can be given to patients ± available 
at: https://www.bhf.org.uk/publications/heart-conditions/m26a-endocarditis-card 
 
The subtle change makes NICE guidance less dogmatic and allows clinicians to use their 
clinical judgment, follow well-accepted international guidelines (12) and provide the care their 
patients want.   
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 Box.  Summary of guidance 
People at high risk:  Replacement heart valves or prior endocarditis 
 
People at moderate risk: Nnative valve disease  
 
High-risk dental procedure: Extractions, root canal treatment, dental scaling and 
other procedures involving manipulation of the gums 
 
Antibiotic prophylaxis : Indicated for people at high-risk having high-risk dental 
procedures.  Record details of consent process in the dental notes. Use 
amoxicillin 3 g or clindamicin 600 mg orally one hour before 
 
Other advice: Ddental surveillance 6 monthly (high-risk people) or annually 
(medium risk people), avoid tattoos and intravenous drug use.   
 
Warning: Consider infective endocarditis with persistentunresolving fever or 
night-sweats especially with systemic symptoms.  Take at least two sets of 
blood cultures before starting an antibiotic course. 
 
